Latest Recruitment News

Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.

HiTech Group Australia delivered a weaker FY2026 profit and lower revenue, but finished with $10.56 million in cash and no debt before completing its Hudson acquisition. The post-year-end deal and $4 million institutional raise now place execution, funding and integration at the centre of the story.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Avenira has pushed its first Wonarah phosphate shipment target into the first half of 2027, while its auditor warned that funding remains critical to the company’s survival. The annual report records project progress, but also a $3.34 million loss, $759,415 in year-end cash and a proposed $49 million rights issue.

TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

SkinKandy Limited (ASX:SK1) exceeded its IPO forecasts in FY26, with pro forma revenue rising 29% to A$90.2 million and pro forma NPAT climbing 41% to A$9.0 million. The newly listed retailer enters FY27 with 115 stores, 11 approved leases and plans for potential expansion into South Africa and the United States.

Prescient Therapeutics has raised approximately $6 million through its Share Purchase Plan and a shortfall placement, giving PTX-100 additional funding beyond a key clinical review in December. The next test is whether early results support a move into Phase 2b development.

TrivarX has moved Stabl-Im closer to human testing, with pre-clinical studies underway, investigational product preparation progressing and clinical site selection now open. The indicative plan targets first participant enrolment in Q1 2027, but key technical and ethics steps remain outstanding.

Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.

Dimerix has drawn A$17 million from a non-dilutive facility, giving the biotech funding it says is sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue developing DMX-652. A further A$17 million remains available, although repayment depends partly on future licensing income, milestones or capital-market access.

Clover Corporation has delivered record FY26 revenue of $97.4 million and a 50% lift in attributable profit, while raising its fully franked final dividend to 1.25 cents per share. The result comes alongside a planned chair transition, with Ian Glasson set to replace retiring chair Rupert Harrington after the 2026 AGM.